Latest Renewables News

Orbminco Limited is proposing a 20 – 1 consolidation of its issued shares to streamline its capital structure and broaden investor appeal, with shareholder approval sought in September.

Ausmon Resources has addressed a recent spike in its share price and trading volume, attributing the market interest to prior drilling assay results for rare earth elements in South Australia.

Anson Resources has successfully raised $5 million through an oversubscribed share placement to fast-track development of its Green River Lithium Project in Utah. The funds will support key engineering, permitting, and resource expansion activities.

Tombador Iron Limited is set to transform itself by acquiring GoviEx Uranium, creating a new ASX-listed uranium company focused on Zambia’s Muntanga Project. This deal includes a significant capital raise and board overhaul, aiming for a November 2025 completion.

The Papua New Guinea Mining Advisory Committee has recommended extending St Barbara's Simberi Mining Lease to 2038, aligning with plans to boost gold production beyond 200,000 ounces annually.

Deterra Royalties reported a 10% revenue increase for FY25, driven by record Mining Area C production and progress at the Thacker Pass lithium project. The company maintains a strong dividend payout while balancing growth investments.

Encounter Resources reports exceptional rare earth and niobium assay results from diamond drilling at its Crean prospect, reinforcing the Aileron project's status as a critical minerals hotspot in Western Australia.

Monadelphous Group Limited reported a robust 12% revenue increase to $2.27 billion and a 35% rise in net profit, driven by strong demand across resources and energy sectors and a record $2.5 billion in new contracts.

Monadelphous Group Limited reported a robust FY25 with $2.27 billion revenue and $158 million net profit, underpinned by strong contract wins and growth in energy and resources sectors.

CSL Limited reported robust FY25 results alongside a sweeping strategic overhaul, including a major cost-saving program and plans to spin off its vaccine unit CSL Seqirus as a standalone ASX-listed company.

CSL Limited posted a 14% rise in net profit for FY2025, underpinned by strong immunoglobulin sales and new product launches, while announcing plans to demerge its vaccines business, CSL Seqirus, to sharpen strategic focus.

Mercury NZ Limited reported a 10% decline in earnings for FY2025 amid challenging generation conditions but is pressing ahead with significant renewable energy investments and raised dividends.